BEYOND MEAT, INC. (BYND): debt financing — Beyond Meat finalizes exchange of 97.44% of 0% convertible notes for 7% notes and 317.8M shares

BEYOND MEAT, INC.

Exchanged $1,120.5M of 0% convertible notes due 2027 (97.44% of outstanding) for new secured notes and common stock.
Issued $209.7M of new 7.00% Convertible Senior Secured Second Lien PIK Toggle Notes due 2030.
Issued 317.8M shares of common stock as part of exchange consideration; massive dilution to existing shareholders.
Remaining $29.5M of old notes still outstanding after final settlement on October 30, 2025.
Exchange reduces debt burden but reflects financial distress; holders accepted distressed exchange.

item 2.03 item 8.01 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

BEYOND MEAT, INC. incurred convertible notes of $209,176,000 at 7.00% maturing due 2030.

Instrument: convertible notes
Principal: $209,176,000
Rate: 7.00%
Maturity: due 2030
Event: incurrence

Exact text from the filing

Following the Final Settlement Date, a total of (i) $209,176,000 in aggregate principal amount of New Convertible Notes (inclusive of $12.5 million in aggregate principal amount of New Convertible Notes as payment to certain holders of Existing Convertible Notes that had entered into a transaction support agreement with the Company relating to the Exchange Offer) and (ii) 316,926,786 New Shares will have been issued by the Company in connection with the Exchange Offer on the Early Settlement Date and the Final Settlement Date.

View on SEC.gov

304 debt financings filed in the last 30 days. Browse all debt financings →

BEYOND MEAT, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-258594

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.